Khan M
Pharmaceuticals (Basel). 2025; 17(12.
PMID: 39770511
PMC: 11677800.
DOI: 10.3390/ph17121669.
Wang J, Fu J, Zhao Y, Liu Q, Yan X, Su J
Int J Mol Sci. 2023; 24(22).
PMID: 38003544
PMC: 10671546.
DOI: 10.3390/ijms242216353.
Khan M, Mohammad T, Malik A, Hassan M, Domashevskiy A
Sci Rep. 2023; 13(1):5073.
PMID: 36977734
PMC: 10050399.
DOI: 10.1038/s41598-023-32073-x.
Xiao L, Wang M, Shi Y, Xu Y, Gao Y, Zhang W
Curr Neuropharmacol. 2022; 21(3):669-686.
PMID: 36043798
PMC: 10207923.
DOI: 10.2174/1570159X20666220830115018.
Uddin M, Ashraf G
Curr Neuropharmacol. 2021; 21(11):2247-2250.
PMID: 34970955
PMC: 10556378.
DOI: 10.2174/1570159X20666211231163544.
Role of Neuron and Glia in Alzheimer's Disease and Associated Vascular Dysfunction.
Bandyopadhyay S
Front Aging Neurosci. 2021; 13:653334.
PMID: 34211387
PMC: 8239194.
DOI: 10.3389/fnagi.2021.653334.
Opioid Modulation of Neuronal Iron and Potential Contributions to NeuroHIV.
Nash B, Irollo E, Brandimarti R, Meucci O
Methods Mol Biol. 2020; 2201:139-162.
PMID: 32975796
PMC: 7641316.
DOI: 10.1007/978-1-0716-0884-5_13.
Iron-responsive-like elements and neurodegenerative ferroptosis.
Rogers J, Cahill C
Learn Mem. 2020; 27(9):395-413.
PMID: 32817306
PMC: 7433652.
DOI: 10.1101/lm.052282.120.
A Preliminary Study of Cu Exposure Effects upon Alzheimer's Amyloid Pathology.
Pilozzi A, Yu Z, Carreras I, Cormier K, Hartley D, Rogers J
Biomolecules. 2020; 10(3).
PMID: 32155778
PMC: 7175127.
DOI: 10.3390/biom10030408.
Alzheimer's Disease and Its Potential Alternative Therapeutics.
Kisby B, Jarrell J, Agar M, Cohen D, Rosin E, Cahill C
J Alzheimers Dis Parkinsonism. 2019; 9(5).
PMID: 31588368
PMC: 6777730.
DOI: 10.4172/2161-0460.1000477.
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.
Wang W, Tailor B, Cohen D, Huang X
EC Pharmacol Toxicol. 2019; 7(7):547-558.
PMID: 31565701
PMC: 6764777.
Targeting the Iron-Response Elements of the mRNAs for the Alzheimer's Amyloid Precursor Protein and Ferritin to Treat Acute Lead and Manganese Neurotoxicity.
Rogers J, Xia N, Wong A, Bakshi R, Cahill C
Int J Mol Sci. 2019; 20(4).
PMID: 30823541
PMC: 6412244.
DOI: 10.3390/ijms20040994.
Untangling Tau and Iron: Exploring the Interaction Between Iron and Tau in Neurodegeneration.
Rao S, Adlard P
Front Mol Neurosci. 2018; 11:276.
PMID: 30174587
PMC: 6108061.
DOI: 10.3389/fnmol.2018.00276.
Iron regulatory protein (IRP)-iron responsive element (IRE) signaling pathway in human neurodegenerative diseases.
Zhou Z, Tan E
Mol Neurodegener. 2017; 12(1):75.
PMID: 29061112
PMC: 5654065.
DOI: 10.1186/s13024-017-0218-4.
Neuroprotection of brain-permeable iron chelator VK-28 against intracerebral hemorrhage in mice.
Li Q, Wan J, Lan X, Han X, Wang Z, Wang J
J Cereb Blood Flow Metab. 2017; 37(9):3110-3123.
PMID: 28534662
PMC: 5584702.
DOI: 10.1177/0271678X17709186.
Alzheimer's disease therapeutics targeted to the control of amyloid precursor protein translation: maintenance of brain iron homeostasis.
Bandyopadhyay S, Rogers J
Biochem Pharmacol. 2014; 88(4):486-94.
PMID: 24513321
PMC: 4064675.
DOI: 10.1016/j.bcp.2014.01.032.
Selective acetylcholinesterase inhibitor activated by acetylcholinesterase releases an active chelator with neurorescuing and anti-amyloid activities.
Zheng H, Youdim M, Fridkin M
ACS Chem Neurosci. 2012; 1(11):737-46.
PMID: 22778810
PMC: 3368637.
DOI: 10.1021/cn100069c.
The anticholinesterase phenserine and its enantiomer posiphen as 5'untranslated-region-directed translation blockers of the Parkinson's alpha synuclein expression.
Mikkilineni S, Cantuti-Castelvetri I, Cahill C, Balliedier A, Greig N, Rogers J
Parkinsons Dis. 2012; 2012:142372.
PMID: 22693681
PMC: 3368596.
DOI: 10.1155/2012/142372.
The alpha-synuclein 5'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen.
Rogers J, Mikkilineni S, Cantuti-Castelvetri I, Smith D, Huang X, Bandyopadhyay S
J Neural Transm (Vienna). 2011; 118(3):493-507.
PMID: 21221670
PMC: 6625511.
DOI: 10.1007/s00702-010-0513-5.
Site-activated chelators derived from anti-Parkinson drug rasagiline as a potential safer and more effective approach to the treatment of Alzheimer's disease.
Zheng H, Fridkin M, Youdim M
Neurochem Res. 2010; 35(12):2117-23.
PMID: 20981484
DOI: 10.1007/s11064-010-0293-1.